GRTS(GRTS)
GRTS
10/14/26
Gritstone bio (GRTS)
Wednesday
3:54 PM
ThesisThe stock's recent performance and ongoing challenges in clinical trial recruitment have led to increased skepticism among investors.
Revenue Outlook
What Moves the Stock
- 01Clinical trial results for Gritstone-001 and Gritstone-002
- 02Partnership announcements with larger pharmaceutical companies
- 03Regulatory approvals for its therapies
- 04Market sentiment around immunotherapy advancements
- 05Grants and collaborations - 100%
- 06Advancements in personalized medicine
- 07Growth of immunotherapy in oncology
FY2023 Snapshot
- Revenue
- $1M
- Rev. Growth
- -85.6%
- Gross Margin
- -470%
- Op. Margin
- -11618%
- Net Margin
- -10405%
- Net Income
- $-138M
- NI Growth
- -22.4%
- EPS
- $-1.20
- 1Y Return
- -53.5%
GRTS Chart
My Notes
- "Market sentiment is cautious as Gritstone navigates significant operational hurdles."
- Moat: Gritstone's proprietary technology offers a unique approach to immunotherapy, but the moat is vulnerable to rapid advancements…
- growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
- Interest rates affect Gritstone's financing costs and the valuation of its future cash flows…
- Watch on earnings: Clinical trial enrollment rates, Cash runway (months until funding is needed), Partnership revenue growth.
One Sentence Summary:
Gritstone bio: the story is balanced — clinical trial results for gritstone-001 and gritstone-002.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance
